Primary Aldosteronism and Obstructive Sleep Apnea: Is This A Bidirectional Relationship?

Abstract

It has been suggested that the high prevalence of obstructive sleep apnea (OSA) in resistant hypertension (RHT) may be related to the high prevalence of primary aldosteronism (PA) in patients with RHT. It has been also hypothesized that the relationship between aldosterone and OSA might be bidirectional. In patients with RHT, it has been shown that aldosterone levels correlate with severity of OSA and that blockade of aldosterone reduces the severity of OSA. It has been postulated that aldosterone worsens OSA by promoting accumulation of fluid, which shifted in the supine position to the neck, contributes to increased upper airway resistance. Also there is growing data that PA is more frequent in patients with OSA and that the treatment of PA positively influences OSA course. Also in some studies it has been shown that patients with OSA are characterized by higher aldosterone levels and higher prevalence of PA than patients without OSA and that causal treatment of OSA might decrease aldosterone levels. Moreover, the recent guideline of the Endocrine Society on management of PA recommends to screen hypertensive patients with OSA for PA.

Key words

aldosterone - obstructive sleep apnea - primary aldosteronism - treatment

• References

• 1 Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17
• 2 Kaplan NM, Victor RG. Primary aldosteronism. In: Kaplan NM, Victor RG. (eds) Kaplan's clinical hypertension. Philadelphia: Wolters Kluwer; 2015: 320-340
• 3 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281
• 4 Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: Long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev 2008; 29: 133-154
• 5 Prejbisz A, Warchol-Celinska E, Lenders JW, Januszewicz A. Cardiovascular Risk in Primary Hyperaldosteronism. Horm Metab Res 2015; 47: 973-980
• 6 Asbach E, Williams TA, Reincke M. Recent developments in primary aldosteronism. Exp Clin Endocrinol Diabetes 2016; 124: 335-341
• 7 Funder JW. Primary aldosteronism: New answers, new questions. Horm Metab Res 2015; 47: 935-940
• 8 Willenberg HS. How to escape from primary aldosteronism? News and views on an adrenal disorder of salt retention. Horm Metab Res 2017; 49: 151-163
• 9 Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young Jr WF. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
• 10 Chahal CA, Somers VK. Secondary hypertension: Obstructive sleep apnea. J Am Soc Hypertens 2015; 9: 244-247 quiz 248
• 11 Florczak E, Prejbisz A, Szwench-Pietrasz E, Sliwinski P, Bielen P, Klisiewicz A, Michalowska I, Warchol E, Januszewicz M, Kala M, Witkowski A, Wiecek A, Narkiewicz K, Somers VK, Januszewicz A. Clinical characteristics of patients with resistant hypertension: the RESIST-POL study. J Hum Hypertens 2013; 27: 678-685
• 12 Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens 2012; 26: 281-287
• 13 Jin ZN, Wei YX. Meta-analysis of effects of obstructive sleep apnea on the renin-angiotensin-aldosterone system. J Geriatr Cardiol 2016; 13: 333-343
• 14 Yang SJ, Jiang XT, Zhang XB, Yin XW, Deng WX. Does continuous positive airway pressure reduce aldosterone levels in patients with obstructive sleep apnea?. Sleep Breath 2016; 20: 921-928
• 15 Grundy HM, Simpson SA, Tait JF. Isolation of a highly active mineralocorticoid from beef adrenal extract. Nature 1952; 169: 795-796
• 16 Svatikova A, Olson LJ, Wolk R, Phillips BG, Adachi T, Schwartz GL, Somers VK. Obstructive sleep apnea and aldosterone. Sleep 2009; 32: 1589-1592
• 17 Muxfeldt ES, Margallo VS, Guimaraes GM, Salles GF. Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension. Am J Hypertens 2014; 27: 1069-1078
• 18 de Souza F, Muxfeldt ES, Margallo V, Cortez AF, Cavalcanti AH, Salles GF. Effects of continuous positive airway pressure treatment on aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension: A randomized controlled trial. J Hypertens 2017; 35: 837-844
• 19 Friedman O, Bradley TD, Chan CT, Parkes R, Logan AG. Relationship between overnight rostral fluid shift and obstructive sleep apnea in drug-resistant hypertension. Hypertension 2010; 56: 1077-1082
• 20 Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168: 1159-1164
• 21 Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007; 131: 453-459
• 22 Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM, Oparil S, Cofield SS, Calhoun DA. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med 2010; 6: 363-368
• 23 Acelajado MC, Calhoun DA. Aldosteronism and resistant hypertension. Int J Hypertens 2011; 2011:837817
• 24 Egan BM, Li J. Role of aldosterone blockade in resistant hypertension. Semin Nephrol 2014; 34: 273-284
• 25 Pimenta E, Stowasser M, Gordon RD, Harding SM, Batlouni M, Zhang B, Oparil S, Calhoun DA. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest 2013; 143: 978-983
• 26 Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens 2010; 24: 532-537
• 27 Kasai T, Bradley TD, Friedman O, Logan AG. Effect of intensified diuretic therapy on overnight rostral fluid shift and obstructive sleep apnoea in patients with uncontrolled hypertension. J Hypertens 2014; 32: 673-680
• 28 Yang L, Zhang H, Cai M, Zou Y, Jiang X, Song L, Liang E, Bian J, Wu H, Hui R. Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea. Clin Exp Hypertens 2016; 38: 464-468
• 29 Krasinska B, Miazga A, Cofta S, Szczepaniak-Chichel L, Trafas T, Krasinski Z, Pawlaczyk-Gabriel K, Tykarski A. Effect of eplerenone on the severity of obstructive sleep apnea and arterial stiffness in patients with resistant arterial hypertension. Pol Arch Med Wewn 2016; 126: 330-339
• 30 Saarelainen S, Hasan J, Siitonen S, Seppala E. Effect of nasal CPAP treatment on plasma volume, aldosterone and 24- h blood pressure in obstructive sleep apnoea. J Sleep Res 1996; 5: 181-185
• 31 Deng G, Qiu ZD, Li DY, Fang Y, Zhang SM. Effects of continuous positive airway pressure therapy on plasma aldosterone levels in patients with obstructive sleep apnea: A meta-analysis. J Huazhong Univ Sci Technolog Med Sci 2016; 36: 619-625
• 32 Lloberes P, Sampol G, Espinel E, Segarra A, Ramon MA, Romero O, Ferrer R, Martinez-Garcia MA, Tovar JL. A randomized controlled study of CPAP effect on plasma aldosterone concentration in patients with resistant hypertension and obstructive sleep apnea. J Hypertens 2014; 32: 1650-1657 discussion 1657
• 33 Zhang XL, Li YQ. Efficacy of continous positive airway pressure therapy upon resistant hypertension in patients with obstructive slle apnea hypopnea sydrome. Zhonghua Yi Xue Za Zhi 2009; 89: 1811-1814
• 34 Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004; 125: 112-117
• 35 Di Murro A, Petramala L, Cotesta D, Zinnamosca L, Crescenzi E, Marinelli C, Saponara M, Letizia C. Renin-angiotensin-aldosterone system in patients with sleep apnoea: Prevalence of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2010; 11: 165-172
• 36 Karcz M, Obarska J, Bobrowski R, Lewko D, Drab M, Kolodziejczyk-Kruk S, Warchol-Celinska E, Pregowska-Chwala B, Janas J, Janaszek-Sitkowska H, Kabat M, Ambroziak U, Bednarczuk T, Sliwinski P, Reincke M, Lenders JWM, Januszewicz A, Prejbisz A. Frequency of primary aldosteronism in patients with obstructive sleep apnea – OSA-PA study. J Hypertens 2017; 35: e39
• 37 Sim JJ, Yan EH, Liu IL, Rasgon SA, Kalantar-Zadeh K, Calhoun DA, Derose SF. Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population. J Hypertens 2011; 29: 1553-1559
• 38 Prejbisz A, Florczak E, Klisiewicz A, Dobrowolski P, Janaszek-Sitkowska H, Bielen P, Szwench-Pietrasz E, Warchol-Celinska E, Kolodziejczyk-Kruk S, Janas J, Kabat M, Imiela J, Sliwinski P, Januszewicz A. Relationship between primary aldosteronism and obstructive sleep apnoea, metabolic abnormalities and cardiac structure in patients with resistant hypertension. Endokrynol Pol 2013; 64: 363-367
• 39 Wolley MJ, Pimenta E, Calhoun D, Gordon RD, Cowley D, Stowasser M. Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea. J Hum Hypertens 2017; 31: 561-567
• 40 Foster GE, Hanly PJ, Ahmed SB, Beaudin AE, Pialoux V, Poulin MJ. Intermittent hypoxia increases arterial blood pressure in humans through a Renin-Angiotensin system-dependent mechanism. Hypertension 2010; 56: 369-377
• 41 Wolley MJ, Pimenta E, Calhoun D, Gordon RD, Cowley D, Stowasser M. Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea. J Hum Hypertens 2017; 31: 561-567
• 42 Moller DS, Lind P, Strunge B, Pedersen EB. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens 2003; 16: 274-280
• 43 Meston N, Davies RJ, Mullins R, Jenkinson C, Wass JA, Stradling JR. Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea. J Intern Med 2003; 254: 447-454
• 44 Barcelo A, Pierola J, Esquinas C, de la Pena M, Arque M, Alonso-Fernandez A, Bauca JM, Robles J, Barcelo B, Barbe F. Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: Effect of continuous positive airway pressure treatment. PLoS One 2014; 9: e84362
• 45 Lacedonia D, Tamisier R, Roche F, Monneret D, Baguet JP, Levy P, Pepin JL. Respective effects of OSA treatment and angiotensin receptor blocker on aldosterone in hypertensive OSA patients: A randomized cross-over controlled trial. Int J Cardiol 2014; 177: 629-631
• 46 Nicholl DD, Hanly PJ, Poulin MJ, Handley GB, Hemmelgarn BR, Sola DY, Ahmed SB. Evaluation of continuous positive airway pressure therapy on renin-angiotensin system activity in obstructive sleep apnea. Am J Respir Crit Care Med 2014; 190: 572-580